Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
27.77
-0.08 (-0.29%)
At close: Apr 28, 2026, 4:00 PM EDT
27.77
0.00 (0.00%)
After-hours: Apr 28, 2026, 6:05 PM EDT
Roivant Sciences Employees
Roivant Sciences had 750 employees as of March 31, 2025. The number of employees decreased by 158 or -17.40% compared to the previous year.
Employees
750
Change (1Y)
-158
Growth (1Y)
-17.40%
Revenue / Employee
$17,747
Profits / Employee
-$1,078,987
Market Cap
19.88B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 750 | -158 | -17.40% |
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Insmed | 1,664 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Revolution Medicines | 883 |
ROIV News
- 26 days ago - Roivant Sciences Transcript: Study result - Transcripts
- 26 days ago - Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) - GlobeNewsWire
- 26 days ago - Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) - GlobeNewsWire
- 4 weeks ago - New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis - GlobeNewsWire
- 6 weeks ago - Roivant Sciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Roivant Sciences Transcript: Status update - Transcripts
- 2 months ago - Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute - Reuters
- 2 months ago - Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna - GlobeNewsWire